Therapeutic potential of dual CDK12 and 13 inhibition in colorectal cancer

被引：0
|
作者：
Altunel, Erdem
Zokaasadi, Mohammad
Somarelli, Jason A.
McCall, Shannon J.
Gultawatvichai, Patan
Whalen, Giles Francis
Pitarresi, Jason
Hsu, David S.
机构：
[1] UMass Chan Med Sch, Div Hematol Oncol, Dept Med, Worcester, MA USA
[2] Duke Univ, Div Med Oncol, Dept Med, Med Ctr, Durham, NC USA
[3] Duke Univ, Dept Pathol, Med Ctr, Durham, NC USA
[4] UMass Chan Med Sch, Div Surg Oncol, Dept Surg, Worcester, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15601
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
    Hamman, Kristin
    Bradley, Michael
    Marineau, Jason
    Choi, Yoon
    Malojcic, Goran
    Orlando, David
    Ren, Yixuan
    Ke, Nan
    Hu, Shanhu
    Olson, Eric
    Fritz, Christian
    Roberts, Christopher
    FASEB JOURNAL, 2017, 31
  • [22] Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
    Bradley, Michael
    Marineau, Jason
    Choi, Yoon
    Hamman, Kristin
    Malojcic, Goran
    Orlando, David
    Ren, Yixuan
    Ke, Nan
    Hu, Shanhu
    Olson, Eric
    Fritz, Christian
    Roberts, Christopher
    CANCER RESEARCH, 2017, 77
  • [23] Cyclin K goes with Cdk12 and Cdk13
    Kohoutek, Jiri
    Blazek, Dalibor
    CELL DIVISION, 2012, 7
  • [24] Cyclin K goes with Cdk12 and Cdk13
    Jiri Kohoutek
    Dalibor Blazek
    Cell Division, 7
  • [25] CDK12 is a novel therapeutic target in glioblastoma
    Mun, Jeong-Yeon
    Shu, Chang
    Gao, Qiuqiang
    Westhoff, Mike-Andrew
    Karpel-Massler, Georg
    Siegelin, Markus D.
    CANCER RESEARCH, 2024, 84 (06)
  • [26] Antitumor effect of dual inhibition of PARP and CDK12 in Uterine serous carcinoma
    Kawahara, Shunsuke
    Hamanishi, Junzo
    Miyamoto, Taito
    Taki, Mana
    Yamanoi, Koji
    Murakami, Ryusuke
    Yamaguchi, Ken
    Yusa, Kosuke
    Mandai, Masaki
    CANCER SCIENCE, 2023, 114 : 1233 - 1233
  • [27] CDK12/13 inhibition antagonizes resistance to KRASG12C inhibitors.
    Stern, Yaakov E.
    Ghosh, Pompom
    Walker-Mimms, Hannah L.
    Mosior, John W.
    Imbody, Denis
    Solanki, Hitendra S.
    Monastyrskyi, Andrii
    Duckett, Derek R.
    Haura, Eric B.
    CANCER RESEARCH, 2022, 82 (23)
  • [28] Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation
    Diaz-Tejeiro, Cristina
    Arenas-Moreira, Maria
    Sanvicente, Adrian
    Paniagua-Herranz, Lucia
    Clemente-Casares, Pilar
    Bravo, Ivan
    Alonso-Moreno, Carlos
    Nieto-Jimenez, Cristina
    Ocana, Alberto
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 178
  • [29] MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma
    Consuelo Pitolli
    Alberto Marini
    Marika Guerra
    Marco Pieraccioli
    Veronica Marabitti
    Fernando Palluzzi
    Luciano Giacò
    Gianpiero Tamburrini
    Francesco Cecconi
    Francesca Nazio
    Claudio Sette
    Vittoria Pagliarini
    Journal of Experimental & Clinical Cancer Research, 42
  • [30] Combination of CDK12 inhibition and olaparib enhances genomic instability in cancer models
    Alnemy, S.
    Rajagopal, N.
    Perera, P.
    Shawgo, R.
    Dworakowski, W.
    LaPlaca, D.
    Carulli, J.
    Chuaqui, C.
    Hu, S.
    Moebius, D.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S53 - S53
12345